)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Syncona
Syncona (SYNC) investor relations material
Syncona H1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2027 earnings summary12 Nov, 2026
Executive summary
NAV per share rose 3.0% to 175.7p in the six months to 30 September 2026; net assets reached £1,068.9m, while the life science portfolio returned 4.7%.
Beacon’s positive pivotal VISTA results drove a £48.5m increase in deferred consideration; 91.7% of portfolio value was in commercial, late-stage clinical or clinical-stage companies.
The focus remains on returning at least £250m to shareholders, with multiple clinical milestones expected through 2028.
Financial highlights
NAV was £1,068.9m at 30 September 2026; life science portfolio value was £920.7m and the capital pool was £148.2m.
Beacon’s valuation rose £48.5m to £238.9m; gains in Autolus and OMass were partly offset by an Anaveon write-down of £24.5m.
Net profit after tax was £31.06m, versus a £25.47m loss in the prior-year period; EPS was 5.11p versus a 4.18p loss.
The share price rose 39.9% to 123.8p, narrowing the discount to NAV to ~29.5%; capital deployed into the Life Science Portfolio was £43.4m.
Outlook and guidance
Five key value inflection points are expected by end-CY2028, including four in the next 12 months; iOnctura, Quell, Purespring and OMass are among the upcoming milestones.
Purespring, OMass and Quell clinical data are expected in CY2027; Spur expects to complete the pivotal stage of its Phase III trial in H2 CY2028.
At least £250m of proceeds is targeted for return to shareholders from private-company exits; portfolio milestones may support NAV growth and potential exits.
Autolus expects FY2026 AUCATZYL net product revenue at or above the upper end of prior guidance of $150m.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Syncona
- Late-stage life sciences portfolio targets major value milestones with strong exit history and leadership.SYNC
Corporate presentation - Stable NAV and advancing clinical milestones set the stage for key value inflection points by CY2026.SYNCQ1 2027 TU
- NAV stable, 1.7% portfolio return, and GBP 250 million in realizations targeted.SYNCH2 2026
- NAV per share rose 3.6% as late-stage clinical assets and Beacon's uplift drove portfolio gains.SYNCQ3 2026 TU
- NAV fell (1.7)% to £1,020.9m; five value inflection points and £250m return targeted.SYNCH1 2026
- NAV per share rose 0.5% as clinical and strategic milestones drove portfolio growth.SYNCQ1 2026 TU
- NAV per share down 9.5% to 170.9p, portfolio 78.5% clinical, strategic plan for cash returns.SYNCH2 2025
- NAV fell 5.2% as late-stage portfolio advanced, with FDA approval and capital inflows supporting growth.SYNCH1 2025
- NAV up 1.2% to GBP 1.2bn, portfolio 71% clinical stage, and GBP 60m buyback supports growth.SYNCH2 2024
Syncona
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Syncona Limited is a closed-ended investment company based in Guernsey, specializing in the life sciences sector. The company's operations focus on founding, building, and funding companies to create a diversified portfolio of 20-25 globally leading healthcare companies.Syncona invests in a range of life sciences companies, including those working in gene therapy, cell therapy, biologics, and small molecule fields. Syncona is headquartered in Saint Peter Port, Guernsey, and its shares are listed on the London Stock Exchange.